Blueprint Medicines is a top-tier, publicly-traded (BPMC) Biopharmaceutical Company focused on discovering, developing and commercializing highly-selective kinase inhibitors for genomically defined diseases. Originally funded by Third Rock Ventures, the company has built a sophisticated genomics platform and a one-of-kind annotated compound collection which is delivering a pipeline of novel therapies. In just three years, four programs have been established in genomically defined cancers and one program in the rare genetic disease space.
The Associate Director of Regulatory Affairs will be responsibility for developing global regulatory strategies to advance Blueprint’s oncology portfolio. Reporting to the Director of Regulatory Affairs, this individual will provide strategic input and operational regulatory support to cross-functional teams responsible for development and registration of Blueprint compounds in orphan oncology indications. The individual will also ensure effective communication and constructive working relationships with external collaborators and regulatory authorities.
WHO WE ARE:
Blueprint Medicines’ mission is to dramatically improve the lives of patients with genomically defined diseases. Our singular focus is to use our deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases to craft highly selective medicines aimed at eradicating these diseases.
We don’t think in small steps. We think in giant leaps.
We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
We know that what each and every one of us does matters and that our success depends on our ability to work together. We believe we are at our best as a company when our employees are thriving and foster a culture that provides opportunities to grow and develop professionally, while also having fun.